|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | LC-01 |
| 用途 | 中间体 |
| 包装规格 | 20mg |
| 纯度 | 98%% |
| CAS编号 | 923564-51-6 |
| 是否进口 | 否 |
联合知名大学科研院所及企业开发药食两用植物标准品和天然植物有效单体，主打中药对照品/标准品/天然植物有效单体，小分子化合物库，药物杂质。所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。
| 常用名 | 生根粉263 | 英文名 | Navitoclax |
|---|---|---|---|
| CAS号 | 923564-51-6 | 分子量 | 974.613 |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | N/A |
| 分子式 | C47H55ClF3N5O6S3 | 熔点 | 114-116oC |
| MSDS | N/A | 闪点 | N/A |
Navitoclax (ABT-263) 是有效，可口服的 Bcl-2 抑制剂，可与Bcl-xL，Bcl-2， Bcl-w等多种Bcl-2家族蛋白结合，Ki 值小于 1 nM。
Fields of Application :
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.
| CAS Number: | 923564-51-6 |
| Purity: | 99% |
| Molecular Weight: | 974.61 |
| Molecular Formula: | C47H55ClF3N5O6S3 |
Quality Control: HPLC、NMR、 LC/MS(Please contact us to get the QC report)
| Synonyms: | ABT263,ABT-263 |
| Chemical Name: | |
| Storage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Note: Products for research use only, not for human use
Description:
ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM. in vitro: ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of<400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. in vivo: ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. For the detailed information about the solubility of ABT-263 in water, the solubility of ABT-263 in DMSO, the solubility of ABT-263 in PBS buffer, the animal experiment（test） of ABT-263,the in vivo,in vitro and clinical trial test of ABT-263,the cell experiment（test） of ABT-263,the IC50, EC50 and Affinity of ABT-263.
